Vivacta Biotechnology
Develops in vivo CAR-T cell therapies for cancer and autoimmune diseases
$50MSeries A+
Role not disclosedLoading investors…
Activity from announced rounds
Develops in vivo CAR-T cell therapies for cancer and autoimmune diseases
Develops intelligent platform-driven macrocyclic peptide drug discovery
Pitching Decheng Capital? Send the deck from a free RoundOS data room and see which pages they read.
Create a free room